JMD GMP oligos for in vitro Diagnostics
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Originally published online as doi:10.2353/jmoldx.2008.080105 on October 2, 2008

Published online before print October 2, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jmoldx.2008.080105v1
10/6/493    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Riely, G. J.
Right arrow Articles by Ladanyi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Riely, G. J.
Right arrow Articles by Ladanyi, M.
Journal of Molecular Diagnostics 2008, Vol. 10, No. 6
Copyright © 2008 American Society for Investigative Pathology & Association for Molecular Pathology
DOI: 10.2353/jmoldx.2008.080105

Commentary

KRAS Mutations

An Old Oncogene Becomes a New Predictive Biomarker

Gregory J. Riely* and Marc Ladanyi{dagger}

From the Thoracic Oncology Service, Department of Medicine, * Department of Pathology and Human Oncology & Pathogenesis Program, {dagger} Memorial Sloan-Kettering Cancer Center, New York, New York

Abstract

This commentary highlights a novel assay for detection of mutations in KRAS, which have recently emerged as a useful negative predictive biomarker.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
S. Ogino, J. A. Meyerhardt, N. Irahara, D. Niedzwiecki, D. Hollis, L. B. Saltz, R. J. Mayer, P. Schaefer, R. Whittom, A. Hantel, et al.
KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803
Clin. Cancer Res., December 1, 2009; 15(23): 7322 - 7329.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. M. Brannan, W. Dong, L. Prudkin, C. Behrens, R. Lotan, B. N. Bekele, I. Wistuba, and F. M. Johnson
Expression of the Receptor Tyrosine Kinase EphA2 Is Increased in Smokers and Predicts Poor Survival in Non-Small Cell Lung Cancer
Clin. Cancer Res., July 1, 2009; 15(13): 4423 - 4430.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. M. Giusti, M. H. Cohen, P. Keegan, and R. Pazdur
FDA Review of a Panitumumab (VectibixTM) Clinical Trial for First-Line Treatment of Metastatic Colorectal Cancer
Oncologist, March 1, 2009; 14(3): 284 - 290.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Society for Investigative Pathology and the Association for Molecular Pathology.